Category Archives: TRIPS flexibilities

Unlikely Alliance Of India, US Could Keep Medicines Access On WHO Agenda

BY CATHERINE SAEZ, INTELLECTUAL PROPERTY WATCH It is not often that on the matter of access to medicines, India and the United States agree at the World Health Organization. But the issue of access to medicines is rising on the … Continue reading

Posted in TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Better life through medicine—let’s leave no one behind

Source: The Lancet Commission on Essential Medicines Policies  rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading

Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Pharmaceuticals & Patents, a talk by Justice Prabha Sridevan

  I am grateful to the Dr. N.S. Gopalakrishnan for inviting me to inaugurate this workshop, the theme being “Pharmaceuticals and patents.” This is a very important one today when there is a claim for a strong patent regime. But I must … Continue reading

Posted in Patent, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

US continue to bully India – Place India again in Special 301 Priority Watch List 2017

Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders across the world.  It points out that India support … Continue reading

Posted in Sec 3 (d), Special 301 report, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, USTR, USTR 301 report | Leave a comment

The expanding universe of IP

Source: The Hindu Granting data exclusivity for clinical trials would undermine access to medicines April 26 is World Intellectual Property (IP) day. Over the years, global IP standards have steadily expanded beyond World Trade Organisation (WTO) requirements, thanks to free … Continue reading

Posted in Data Exclusivity, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Eli Lilly’s ISDS Patent Claim against Canada Defeated

In an unprecedented case, Eli Lilly initiated an amended investor-state-dispute-settlement (ISDS) claim against the government of Canada in 2013 after Canada’s highest courts upheld invalidations on new therapeutic use patents for two chemical compounds – olanzapine and atomoxetine, the active … Continue reading

Posted in Compulsory Licensing, FTA, Investor state dispute, Uncategorized | Leave a comment

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment